Exklusive Humanmilch bei Frühgeborenen und frühen vaskularen Alterungsrisikofaktoren (NEOVASC) (NEOVASC)
Auswirkungen einer ausschließlichen Ernährung mit Muttermilch bei Frühgeborenen auf die Risikofaktoren der frühen vaskulären Alterung (NEOVASC)
Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.
The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:
- An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
- Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.
The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Ursula Kiechl-Kohlendorfer, MD, MSc
- Telefonnummer: +43 512 504 27309
- E-Mail: ursula.kohlendorfer@i-med.ac.at
Studieren Sie die Kontaktsicherung
- Name: Wolfgang Mitterer, MD
- Telefonnummer: +43 670 2021490
- E-Mail: wolfgang.mitterer@student.i-med.ac.at
Studienorte
-
-
Tyrol
-
Innsbruck, Tyrol, Österreich, A-6020
- Rekrutierung
- Medical University of Innsbruck
-
Kontakt:
- Ursula Kiechl-Kohlendorfer, MD, MSc
- Telefonnummer: +43 512 504 27309
- E-Mail: ursula.kohlendorfer@i-med.ac.at
-
Kontakt:
- Wolfgang Mitterer, MD
- E-Mail: wolfgang.mitterer@student.i-med.ac.at
-
Hauptermittler:
- Christoph Binder, MD
-
Hauptermittler:
- Martin Wald, MD
-
Hauptermittler:
- Burkhard Simma, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Preterm-born group:
Inclusion Criteria:
- Extremely preterm infants with a birth weight of 500-1250g.
- Feeding is NPO or exclusive human milk prior to enrollment.
- Parent(s) willing to sign informed consent.-
Exclusion Criteria:
- Infants with a birth weight <500g or >1250g
- Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
- Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
- Presence of major congenital malformation.
- Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
- Parent(s) not willing to sign informed consent.
- Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).
Term-born group:
Inclusion criteria
- Term-born children with an adequate birth weight
- Parent(s) willing to sign informed consent
Exclusion criteria
- Subjects with acute or chronic illness
- Parent(s) not willing to sign informed consent
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Randomized study product group
receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
Aktiver Komparator: Randomized control group
receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
Kein Eingriff: Term control group
Term-born controls as a reference group for outcome parameters |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fasting blood glucose
Zeitfenster: "First day of life" up to "five years of life"
|
Primary outcome is the difference in fasting blood glucose at five years of age |
"First day of life" up to "five years of life"
|
|
Blood pressure
Zeitfenster: "First day of life" up to "five years"
|
Primary outcome is the difference in blood pressure at five years of age |
"First day of life" up to "five years"
|
|
Distensibility of aorta
Zeitfenster: "First day of life" up to "five years"
|
Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age |
"First day of life" up to "five years"
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fasting blood glucose
Zeitfenster: "First day of life" up to "24 months"
|
Secondary outcome is fasting glucose at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
Blood pressure
Zeitfenster: "First day of life" up to "24 months"
|
Secondary outcome is blood pressure at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
BMI
Zeitfenster: "First day of life" up to "five years"
|
Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"First day of life" up to "five years"
|
|
Insulin sensitivity
Zeitfenster: "First day of life" up to "five years"
|
Secondary outcome is insulin sensitivity at five years of age |
"First day of life" up to "five years"
|
|
Lipid profile
Zeitfenster: "First day of life" up to "five years"
|
Secondary outcome is lipid profile at five years of age |
"First day of life" up to "five years"
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fasting blood glucose
Zeitfenster: "five years of age"
|
Difference in fasting blood glucose between preterm- and term-born children at five years of age |
"five years of age"
|
|
Blood pressure
Zeitfenster: "five years of age"
|
Difference in blood pressure between preterm- and term-born children at five years of age |
"five years of age"
|
|
Distensibility of the descending aorta
Zeitfenster: "five years of age"
|
Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children |
"five years of age"
|
|
BMI
Zeitfenster: "five years of age"
|
Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"five years of age"
|
|
Insulin sensitivity
Zeitfenster: "five years of age"
|
Difference in insulin sensitivity between preterm- and term-born children at five years of age |
"five years of age"
|
|
Lipid profile
Zeitfenster: "five years of age"
|
Difference in lipid profile between preterm- and term-born children at five years of age |
"five years of age"
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Ursula Kiechl-Kohlendorfer, MD, MSc, Medical University Innsbruck
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NEOVASC
- 868624 (Andere Zuschuss-/Finanzierungsnummer: Austrian Research Promotion Agency)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .